Pennsaid 2%

Topical NSAID  –  Combines 2% diclofenac sodium with the transdermal drug carrier dimethyl sulfoxide (DMSO)

Indication

  • Treating the pain of osteoarthritis of the knee

Benefits

  • Low systemic exposure to minimize side effects
  • First twice per day dosing topical NSAID in the U.S.
  • Metered dose dispenser

Commercial Status

  • Marketed in the U.S. by Horizon Pharma plc – January 2015

Intellectual Property

  • Patents issued in nineteen countries (ex-U.S.) and pending in five countries with the latest expiring 2027
  • Pennsaid Pump patent applications pending in eleven countries through 2033

Website